← Back to Clinical Trials
Recruiting NCT06036810

NCT06036810 Spanish Decision Tool for Ovarian Cancer Maintenance Therapy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06036810
Status Recruiting
Phase
Sponsor M.D. Anderson Cancer Center
Condition Ovarian Cancer
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2023-08-31
Primary Completion 2027-10-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Shared Medical Decision ToolEngaging Patients in Decision MakingLiteracy Spanish Language

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 70 participants in total. It began in 2023-08-31 with a primary completion date of 2027-10-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To develop a shared decision-making (SDM) tool to help Spanish-speaking patients make decisions about their maintenance therapy

Eligibility Criteria

Study population: This study will enroll patients and clinical providers. Inclusion criteria: Patients • Eligible patients must be: 1) individuals ≥ 18 years with advanced stage high grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are receiving or have completed platinum-based chemotherapy for ovarian cancer and are potentially eligible to receive maintenance therapy; 2) able to understand, speak or read in Spanish. Exclusion criteria: Patients • Inability or unwillingness to sign informed consent Inclusion criteria: Clinicians • Eligible clinicians will include: 1) MD Anderson gynecologic oncologists and advanced practice providers who practice at the Houston Area Locations (HALs), MD Anderson Cancer Center, or our county safety net hospital, The Harris Health System (LBJ Hospital). Exclusion criteria: Clinicians • Inability or unwillingness to sign informed consent

Contact & Investigator

Central Contact

Larissa Meyer, M D

✉ Lmeyer@mdanderson.org

📞 (713) 745-0973

Principal Investigator

Larissa Meyer, Meyer

PRINCIPAL INVESTIGATOR

M.D. Anderson Cancer Center

Frequently Asked Questions

Who can join the NCT06036810 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06036810 currently recruiting?

Yes, NCT06036810 is actively recruiting participants. Contact the research team at Lmeyer@mdanderson.org for enrollment information.

Where is the NCT06036810 trial being conducted?

This trial is being conducted at Houston, United States.

Who is sponsoring the NCT06036810 clinical trial?

NCT06036810 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Larissa Meyer, Meyer at M.D. Anderson Cancer Center. The trial plans to enroll 70 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology